Sökning: onr:"swepub:oai:DiVA.org:umu-156421" >
Molecular epidemiol...
Molecular epidemiology approach : nested case-control studies in glioma and lymphoid malignancies
-
- Späth, Florentin, 1980- (författare)
- Umeå universitet,Onkologi
-
- Melin, Beatrice S., Professor (preses)
- Umeå universitet,Onkologi
-
- Wibom, Carl (preses)
- Umeå universitet,Onkologi
-
visa fler...
-
- Johansson, Ann Sofie (preses)
- Umeå universitet,Onkologi
-
- Bergdahl, Ingvar, Lektor (preses)
- Umeå universitet,Enheten för biobanksforskning
-
- Landgren, Ola, Professor (opponent)
- Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, USA
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789178550258
- Umeå : Umeå universitet, 2019
- Engelska 53 s.
-
Serie: Umeå University medical dissertations, 0346-6612 ; 2016
- Relaterad länk:
-
https://umu.diva-por...
-
visa fler...
-
https://umu.diva-por...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Nested case-control studies aim to link molecular markers with a certain outcome. Repeated prediagnostic samples may improve the evaluation of marker-disease associations. However, data regarding the benefit of repeated samples in such studies are sparse. We aimed to assess the relationship between blood levels of various proteins and risk of glioma, B cell lymphoma, and multiple myeloma to gain further understanding of disease etiology and to evaluate the clinical relevance of the studied markers. To this end, marker-disease associations were evaluated considering the natural history of the studied disease and the time between blood sample collection and diagnosis using both single (I-II) and repeated prediagnostic blood samples (III-IV).PATIENTS AND METHODS: We conducted four nested case-control studies and one meta-analysis using samples from three prospective cohorts: the Janus Serum Bank, the Northern Sweden Health and Disease study, and the European Prospective Investigation into Cancer and Nutrition study. The following studied endpoints and relationships were included: I) glioma risk and the association with the receptor tyrosine kinases (soluble) sEGFR and sERBB2; II) B cell lymphoma risk and the association with the immune markers sCD27 and sCD30; III) B cell lymphoma risk and the association with immune markers (CXCL13, sTNF-R1, sCD23, sCD27, and sCD30) and their trends over time; and IV) multiple myeloma risk and the association with ten immune markers and growth factors (MCP-3, MIP-1α, MIP-1β, VEGF, FGF-2, fractalkine, TGF-α, IL-13, TNF-α, and IL-10) and their trends over time.RESULTS: Risk of developing I) glioma was weakly associated with high blood levels of sERBB2. In addition, high levels of both sEGFR and sERBB2 assessed 15 years before diagnosis were associated with glioblastoma risk.Risk of II) B cell lymphoma was associated with high levels of sCD30, whereas high levels of sCD27 were particularly associated with risk of chronic lymphocytic leukemia. Meta-analyses showed consistent results for sCD30 across cohorts and lymphoma subtypes, whereas results for sCD27 were less consistent across cohorts and subtypes.In addition, III) B cell lymphoma risk was associated with levels of CXCL13, sCD23, sCD27, and sCD30 assessed in samples collected 17 years before diagnosis. Marker levels increased in cases closer to diagnosis, particularly for indolent lymphoma with a marked association for chronic lymphocytic leukemia and sCD23. Increasing marker levels closer to diagnosis were also observed for CXCL13 in future diffuse large B cell lymphoma patients.Risk of IV) multiple myeloma was associated with low levels of MCP-3, VEGF, FGF-2, fractalkine, and TGF-α. Levels of these markers decreased in myeloma cases over time, especially for TGF-α. TGF-α assessed at time of the prediagnostic repeated sample seemed to help predict progression to multiple myeloma.CONCLUSIONS: Both the natural history of the studied disease and the time between sample collection and diagnosis are crucial for the evaluation of marker-disease associations. Using repeated blood samples improves the understanding of marker-disease associations and might help to identify useful biomarker candidates.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Glioma
- B cell lymphoma
- multiple myeloma
- risk
- repeated samples
- prospective longitudinal study
- nested case-control study
- circulating sEGFR and sERBB2
- circulating immune markers and growth factors
- marker disease association
- disease progression
- NSHDS
- Janus
- linear mixed modeling
- epidemiologi
- Epidemiology
- Oncology
- onkologi
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas